Global Short-read Sequencing Market by Technology (Sanger Sequencing, Next Generation Sequencing) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Industry Insights

Global short-read sequencing market was valued at USD 8.80 Billion in 2018. It is forecast to grow at a CAGR 11.32% over the forecast period. The growth is expected to be driven by a growing demand for personalized medicine, and companion diagnostics. The technology is simple to use and affordable, and short reads can be generated in one run. These benefits are expected to fuel further growth.

Targeted cancer therapies have significantly increased the use of companion diagnostics sequencing technologies. Next-generation Sequencing (NGS-based) methods are a great choice for targeted therapies in precision medicine. This is due to the ability of NGS platforms to measure different biomarkers and map genomic sequences within a single test.

Market revenue will also be boosted by a drop in genome sequencing costs. The National Human Genome Research Institute, (NHGRI) states that genome sequencing costs are decreasing. The cost per megabyte has dropped from USD 5,292.39/Mb in 2001 to USD 0.14/Mb in 2019.

Market leaders are expected to take more market share in the near future. For instance, in March 2019, Illumina entered into a partnership with Boai NKY Medical Holdings, a China-based producer of polyvinylpyrrolidone, to develop NGS-based systems for in-vitro diagnosis of hereditary diseases. These new systems will be created using NKY's analysis software, library prep kits, and Illumina's MiniSeq.

Technology Insights

The largest share of the short-read market's revenue in 2018 was. This technology is a cost-effective and fast way to detect genetic abnormalities. NGS's ability to sequence millions upon millions of DNA fragments simultaneously is expected to increase the use of NGS-based protocols.

Sanger sequencing is ideal for analyzing a single nucleotide fragment at once. It is cost-effective and quick when there are only a few targets (usually between 1 and 20). Segment growth is slowed by the low sensitivity and scalability in Sanger methods, as compared to NGS.

Product Insights

End users must purchase consumables at regular intervals to conduct genome analysis. This is due to the increased consumption in multiple sequence runs. The segment accounted for a large share in 2018. This has resulted in a substantial share of the segment in 2018. Automated instruments have made it easier to use many of the genome analysis platforms on the market.

CAGR for the services segment will be the fastest during the forecast period. Illumina and Roche are key players offering a broad range of NGS-based short read sequencing services at special pricing to academic researchers. This helps boost research in this area.

Application Insights

In 2018, the oncology segment held a significant market share and will continue to dominate throughout the forecast period. Modern platforms make it easier to sequence cancer genes from multiple genomes. This allows medical professionals to analyze the genetic makeup and recommend therapeutic treatments accordingly.

Foundation Medicine offers actionable pancancer panels that can be used for NGS-based targeted sequence. This allows physicians to tailor treatment and choose the best therapy for each patient based on their tumor genotype. It also allows targeted drug development. Myriad Genetics also offers genetic testing via its myRisk product. This allows you to determine if you are at higher risk for developing certain types of cancer.

Workflow insights

As the most critical phase of the entire workflow, sequencing accounted for the largest share of 2018's market for short-read sequences. This step generates additional revenue due to its penetration by market participants.

The high competition on the market led to the creation of portable platforms that are easy to use to sequence DNA. These platforms include NovaSeq and iSeq as well as series from Illumina, IonS5 and Ion Proton and PGM from Thermo Fisher Scientific. This research is done by these companies to lessen the negative impact of short-read protocols.

End-Use Information

The largest market share was held by academic research in 2018. The availability of data analysis platforms at discounted licensing prices to universities will drive growth in research projects. These institutes receive several research grants, which contributes to the higher revenue generation.

The academic research segment is expected to grow in popularity due to increased usage of sequencing methods in research, academic workshops and on-site bioinformatics courses offered at universities. The demand for advanced technologies in clinical diagnostics is another driver of growth for the clinical research segment.

Regional Insights

With a market share of 40%, North America dominated the short-read sequencing market in 2018, with Europe closely following. The key contributor to the estimated revenue share is the availability of a regulatory environment that supports the development of genomics. The regional market growth is further bolstered by the presence of key players such as Roche and Illumina, with well-established distribution networks throughout the region.

Asia Pacific will see the greatest growth due to the evolving reimbursement system in Asia's developing economies. The projected growth rate will be supported by the penetration of dominant players in emerging market markets through acquisitions or collaborative agreements.

Market Share Insights: Short-read Sequencing Market

Thermo Fisher Scientific Inc., Hoffmann-La Roche AG, Qiagen N.V., Illumina, Inc., Genewiz, Genscript Biotech Corporation, 10x Genomics, Macrogen, Inc., Agilent Technologies, BGI Genomics, Fasteris SA, and GE Healthcare are key players in this market.

These companies are focused on novel product launches, acquisition/collaboration with other companies, and expansions of their current businesses in lucrative geographical regions. In January 2018, Illumina and Thermo Fisher Scientific entered into a commercial agreement for the sale of Illumina's Ion AmpliSeq technology. This will be used for research purposes.

The Report Covers Certain Segments

This report provides a forecast of revenue growth at the global, regional and country level and analyzes the current market trends in each sub-segment from 2014 to 2025. Grand View Research analyzed the global short-read sequencing industry report by technology, product, app, workflow, region, and end-use.

• Technology Outlook (Revenue USD Million, 2014-2025)

  • Next-Generation Sequencing

  • Sanger Sequencing

• Product Outlook (Revenue USD Million, 2014-2025)

  • Instruments

  • Consumables

  • Services

• App Outlook (Revenue USD Million, 2014-2025)

  • Oncology

  • Clinical Investigation

  • Reproductive Health

  • HLA Typing/Immune System Monitoring

  • Metagenomics, Epidemiology & Drug Development

  • Agrigenomics & Forensics

  • Consumer Genomics

• Workflow Outlook (Revenue USD Million, 2014-2025)

  • Pre-Sequencing

  • Sequencing

  • Data Analysis

• End Use Outlook (Revenue USD Million, 2014-2025)

  • Academic Research

  • Clinical Research

  • Hospitals & Clinics

  • Pharma & Biotech Entities

  • Other

• Regional Outlook (Revenue USD Million, 2014-2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • The U.K.

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

  • MEA

    • South Africa

Up Market Research published a new report titled “Short-read Sequencing Market research report which is segmented by Technology (Sanger Sequencing, Next Generation Sequencing), By Players/Companies Thermo Fisher Scientific Inc; Hoffmann-La Roche AG; Qiagen NV; Illumina, Inc; Genewiz; Genscript Biotech Corporation; 10x Genomics; Macrogen, Inc; Agilent Technologies; BGI Genomics; Fasteris SA; and GE healthcare”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Short-read Sequencing Market Report Segments:

The market is segmented by Technology (Sanger Sequencing, Next Generation Sequencing).

Short-read Sequencing Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Short-read Sequencing Market

Overview of the regional outlook of the Short-read Sequencing Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Short-read Sequencing Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Short-read Sequencing Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Sanger Sequencing

                2. Next Generation Sequencing

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Short-read Sequencing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Short-read Sequencing Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.